Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | AKT2 | P31751 | 6/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 3/20 | 0.45 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.40 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18291404 | 0.76 | PIK3CD (0.52) | FEN1AKT2AKT1CHEK1CHEK2 | |
| SCHEMBL21162001 | 0.76 | MAPK8 (0.44) | FEN1MAPK1AKT2AKT1PIM1 | |
| SCHEMBL3740850 | 0.75 | AKT2 (0.70) | MAPK1AKT2AKT1PIM1PIM3 | |
| SCHEMBL14896650 | 0.74 | CHEK1 (0.52) | FEN1MAPK1AKT2AKT1PIM1 | |
| SCHEMBL12204196 | 0.72 | AKT2 (0.50) | FEN1MAPK1AKT2AKT1CHEK1 | |
| Hydrochloric Acid SCHEMBL28973063 | 0.72 | AKT2 (0.67) | MAPK1AKT2AKT1PIM1PIM3 | |
| SCHEMBL31157120 | 0.71 | MAPK1 (0.40) | FEN1MAPK1AKT2AKT1PIM1 | |
| SCHEMBL29689263 | 0.71 | AKT2 (0.54) | MAPK1AKT2AKT1PIM1PIM3 | |
| SCHEMBL21861348 | 0.71 | AKT1 (0.44) | MAPK1AKT2AKT1PIM1PIM3 | |
| SCHEMBL17685142 | 0.71 | AKT2 (0.48) | FEN1MAPK1AKT2AKT1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3365335-B1 | 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA INC (US) | 2024-02-14 | — | — | EP | disclosed |
| US-10766881-B2 | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases | ARRAY BIOPHARMA INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20190300511-A1 | 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA INC. | 2019-10-03 | — | — | US | disclosed |
| US-10208024-B2 | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases | ARRAY BIOPHARMA INC. (US) | 2019-02-19 | — | — | US | disclosed |
| EP-3365335-A1 | 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | Array Biopharma, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| US-20170260168-A1 | 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA, INC. | 2017-09-14 | — | — | US | disclosed |
| WO-2017070708-A1 | 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300511-A1 | 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | FGFR1, FGFR2, FGFR3 | FEN1 2857/4885MAPK1 502/4885AKT2 1377/4885 |
| US-10766881-B2 | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases | FGFR1, FGFR2, FGFR3 | FEN1 2857/4885MAPK1 502/4885AKT2 1377/4885 |
| US-10208024-B2 | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases | FGFR1, FGFR2, FGFR3 | FEN1 2857/4885MAPK1 502/4885AKT2 1377/4885 |
| US-20170260168-A1 | 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | FGFR1, FGFR2, FGFR3 | FEN1 2857/4885MAPK1 502/4885AKT2 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.